{"component": "clause", "props": {"groups": [{"size": 8, "snippet": "The Research Program will be carried out during the two (2) year period following the Effective Date, unless this Agreement is terminated in accordance with Article 13 (such period, as may be extended pursuant to this Section 3.2, being the \u201cResearch Term\u201d). BMS shall have the option to extend the Research Term for three (3) additional one (1) year periods on a year-by-year basis after the initial two (2) year period. At least one hundred eighty (180) days prior to the scheduled expiration of the Research Term (i.e., the applicable anniversary of the Effective Date) BMS will provide Ambrx with a nonbinding, good faith indication of whether or not BMS intends to extend the Research Term. In order to exercise its option to extend the Research Term, BMS must provide Ambrx a written notice exercising BMS\u2019 option to extend the Research Term at least ninety (90) days prior to the scheduled expiration of the Research Term (i.e., the applicable anniversary of the Effective Date). If BMS does not provide such written notice, the Research Term will end when scheduled (i.e., on the applicable anniversary of the Effective Date). For each extension of the Research Term, subject to Section 3.4, the JRC will prepare an update to the Research Plan which will include an updated Budget for the BMS-funded Ambrx FTEs to perform the work required under such Research Plan and the projected Third Party Costs.", "samples": [{"hash": "iUNmoR2wqWA", "uri": "/contracts/iUNmoR2wqWA#research-term", "label": "Collaboration and License Agreement (Ambrx Biopharma Inc.)", "score": 32.4031486511, "published": true}, {"hash": "dCQF4sNilTb", "uri": "/contracts/dCQF4sNilTb#research-term", "label": "Collaboration and License Agreement (Ambrx Biopharma Inc.)", "score": 32.4031486511, "published": true}, {"hash": "gYVTh1S5WGx", "uri": "/contracts/gYVTh1S5WGx#research-term", "label": "Collaboration and License Agreement (Ambrx Biopharma Inc.)", "score": 32.2005462646, "published": true}], "snippet_links": [{"key": "the-research-program", "type": "clause", "offset": [0, 20]}, {"key": "year-period", "type": "definition", "offset": [60, 71]}, {"key": "following-the-effective-date", "type": "clause", "offset": [72, 100]}, {"key": "unless-this-agreement", "type": "clause", "offset": [102, 123]}, {"key": "in-accordance-with", "type": "definition", "offset": [138, 156]}, {"key": "article-13", "type": "definition", "offset": [157, 167]}, {"key": "pursuant-to", "type": "clause", "offset": [201, 212]}, {"key": "section-32", "type": "clause", "offset": [218, 229]}, {"key": "option-to-extend", "type": "definition", "offset": [278, 294]}, {"key": "a-year", "type": "definition", "offset": [362, 368]}, {"key": "prior-to-the", "type": "clause", "offset": [461, 473]}, {"key": "expiration-of-the-research-term", "type": "clause", "offset": [484, 515]}, {"key": "applicable-anniversary", "type": "definition", "offset": [527, 549]}, {"key": "will-provide", "type": "clause", "offset": [577, 589]}, {"key": "good-faith", "type": "clause", "offset": [615, 625]}, {"key": "to-exercise", "type": "clause", "offset": [705, 716]}, {"key": "written-notice", "type": "definition", "offset": [782, 796]}, {"key": "extension-of-the-research-term", "type": "clause", "offset": [1144, 1174]}, {"key": "section-34", "type": "clause", "offset": [1187, 1198]}, {"key": "the-jrc", "type": "clause", "offset": [1200, 1207]}, {"key": "research-plan", "type": "definition", "offset": [1238, 1251]}, {"key": "updated-budget", "type": "definition", "offset": [1274, 1288]}, {"key": "work-required", "type": "clause", "offset": [1334, 1347]}, {"key": "third-party-costs", "type": "clause", "offset": [1391, 1408]}], "hash": "8056d2dbceb09bf1d9741755a9eca4ac", "id": 1}, {"size": 7, "snippet": "(a) The Preclinical Development Program with respect to each Collaboration Target will be carried out during the two (2) year period following (x) the Effective Date, with respect to the Initial Collaboration Targets, and (y) the date of designation of a Substitute Target or an Additional Target, with respect to any such Substitute Target or Additional Target, unless (in each case) this Agreement is terminated in accordance with Article 13 (such period, as may be extended pursuant to this Section 3.2, being the \u201cResearch Term\u201d). BMS shall have the option to extend the Research Term with respect to any Collaboration Target for up to three (3) additional one (1) year periods on a year-by-year basis after (x) the initial two (2) year period with respect to such Collaboration Target. In order to exercise its option to extend the Research Term with respect to a given Collaboration Target, BMS must provide CytomX a written notice exercising BMS\u2019 option to extend the applicable Research Term at least [***] prior to the scheduled expiration of the applicable Research Term (i.e., the applicable anniversary of the Effective Date, with respect to the Initial Collaboration Targets, or the date of designation of a Substitute Target or an Additional Target, with respect to any such Substitute Target or Additional Target). If BMS does not provide such written notice, the Research Term will end when scheduled (i.e., on the applicable anniversary of the Effective Date, with respect to the Initial Collaboration Targets, and the date of designation of a Substitute Target or an Additional Target, with respect to any such Substitute Target or Additional Target).\n(b) For each extension of the Research Term, subject to Section 3.4, the JRC will prepare, and approve in accordance with Section 2.1, an update to the Preclinical Plan which will include an updated Budget for the BMS-funded CytomX FTEs to perform the work required under such Preclinical Plan and any projected Third Party Costs.", "samples": [{"hash": "l0LQbJsnKod", "uri": "/contracts/l0LQbJsnKod#research-term", "label": "Collaboration and License Agreement (CytomX Therapeutics, Inc.)", "score": 26.7385349274, "published": true}, {"hash": "eif2s9dNKZo", "uri": "/contracts/eif2s9dNKZo#research-term", "label": "Collaboration and License Agreement (CytomX Therapeutics, Inc.)", "score": 26.7111568451, "published": true}, {"hash": "lhdJd3SoagT", "uri": "/contracts/lhdJd3SoagT#research-term", "label": "Collaboration and License Agreement (CytomX Therapeutics, Inc.)", "score": 26.6536617279, "published": true}], "snippet_links": [{"key": "preclinical-development-program", "type": "definition", "offset": [8, 39]}, {"key": "with-respect-to", "type": "clause", "offset": [40, 55]}, {"key": "year-period", "type": "definition", "offset": [121, 132]}, {"key": "the-effective-date", "type": "clause", "offset": [147, 165]}, {"key": "initial-collaboration-targets", "type": "clause", "offset": [187, 216]}, {"key": "date-of", "type": "clause", "offset": [230, 237]}, {"key": "designation-of-a", "type": "clause", "offset": [238, 254]}, {"key": "substitute-target", "type": "definition", "offset": [255, 272]}, {"key": "additional-target", "type": "definition", "offset": [279, 296]}, {"key": "each-case", "type": "definition", "offset": [374, 383]}, {"key": "this-agreement", "type": "clause", "offset": [385, 399]}, {"key": "in-accordance-with", "type": "definition", "offset": [414, 432]}, {"key": "article-13", "type": "definition", "offset": [433, 443]}, {"key": "pursuant-to", "type": "clause", "offset": [477, 488]}, {"key": "section-32", "type": "clause", "offset": [494, 505]}, {"key": "option-to-extend", "type": "definition", "offset": [554, 570]}, {"key": "a-year", "type": "definition", "offset": [685, 691]}, {"key": "to-exercise", "type": "clause", "offset": [800, 811]}, {"key": "written-notice", "type": "definition", "offset": [923, 937]}, {"key": "the-applicable", "type": "clause", "offset": [971, 985]}, {"key": "prior-to-the", "type": "clause", "offset": [1015, 1027]}, {"key": "expiration-of-the", "type": "clause", "offset": [1038, 1055]}, {"key": "applicable-anniversary", "type": "definition", "offset": [1092, 1114]}, {"key": "extension-of-the-research-term", "type": "clause", "offset": [1683, 1713]}, {"key": "section-34", "type": "clause", "offset": [1726, 1737]}, {"key": "the-jrc", "type": "clause", "offset": [1739, 1746]}, {"key": "section-21", "type": "clause", "offset": [1792, 1803]}, {"key": "preclinical-plan", "type": "clause", "offset": [1822, 1838]}, {"key": "updated-budget", "type": "definition", "offset": [1861, 1875]}, {"key": "work-required", "type": "clause", "offset": [1922, 1935]}, {"key": "third-party-costs", "type": "clause", "offset": [1982, 1999]}], "hash": "1d65f0476ba68e150501937edd8994bc", "id": 2}, {"size": 5, "snippet": "The RESEARCH PROGRAM shall commence on the EFFECTIVE DATE and continue for two (2) years thereafter (such period and any extension thereof referred to as the \"RESEARCH TERM\"). The RESEARCH TERM may be extended as follows: (i) the RESEARCH TERM shall automatically be emended to include any CONTINGENT WORK undertaken by the parties pursuant to Section 2.6.4; (ii) RWJPRI shall have the one-time option, exercisable by written notice to KOSAN not later than ninety (90) days prior to the expiration of the then-current RESEARCH TERM, to extend the RESEARCH TERM for one additional period of up to six (6) months at the level of funding and FTE rate applicable to the preceding six (6) month period, unless otherwise agreed by the JRC; and (iii) the RESEARCH PROGRAM may be extended by mutual written agreement of KOSAN and LICENSEE.", "samples": [{"hash": "jygzkJpU4Hl", "uri": "/contracts/jygzkJpU4Hl#research-term", "label": "Research and License Agreement (Kosan Biosciences Inc)", "score": 18.0, "published": true}, {"hash": "iYCKDMsqOUs", "uri": "/contracts/iYCKDMsqOUs#research-term", "label": "Research and License Agreement (Kosan Biosciences Inc)", "score": 18.0, "published": true}, {"hash": "iIfKFyUZgJf", "uri": "/contracts/iIfKFyUZgJf#research-term", "label": "Research and License Agreement (Kosan Biosciences Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "the-research-program", "type": "clause", "offset": [0, 20]}, {"key": "on-the-effective-date", "type": "clause", "offset": [36, 57]}, {"key": "years-thereafter", "type": "clause", "offset": [83, 99]}, {"key": "contingent-work", "type": "definition", "offset": [290, 305]}, {"key": "by-the-parties", "type": "clause", "offset": [317, 331]}, {"key": "pursuant-to-section", "type": "definition", "offset": [332, 351]}, {"key": "time-option", "type": "definition", "offset": [390, 401]}, {"key": "to-kosan", "type": "clause", "offset": [433, 441]}, {"key": "prior-to-the", "type": "clause", "offset": [474, 486]}, {"key": "expiration-of-the", "type": "clause", "offset": [487, 504]}, {"key": "to-extend", "type": "clause", "offset": [533, 542]}, {"key": "period-of", "type": "clause", "offset": [580, 589]}, {"key": "level-of-funding", "type": "clause", "offset": [618, 634]}, {"key": "applicable-to", "type": "definition", "offset": [648, 661]}, {"key": "agreed-by", "type": "clause", "offset": [715, 724]}, {"key": "the-jrc", "type": "clause", "offset": [725, 732]}, {"key": "mutual-written-agreement", "type": "clause", "offset": [784, 808]}], "hash": "0b82368b83ba29ccbea2dd2c9a72f1d2", "id": 3}, {"size": 5, "snippet": "The Research Program shall commence on the Effective Date and shall conclude four (4) years thereafter (such period, the \u201cResearch Term\u201d). The Research Term may be extended as the Parties determine upon mutual written agreement.", "samples": [{"hash": "fEp0575XKcv", "uri": "/contracts/fEp0575XKcv#research-term", "label": "Research Collaboration and License Agreement", "score": 32.0863380432, "published": true}, {"hash": "kHC0sguBoyH", "uri": "/contracts/kHC0sguBoyH#research-term", "label": "Research Collaboration and License Agreement (AbCellera Biologics Inc.)", "score": 31.8856945038, "published": true}, {"hash": "4FfddGSdeUz", "uri": "/contracts/4FfddGSdeUz#research-term", "label": "Research Collaboration and License Agreement (AbCellera Biologics Inc.)", "score": 31.8473644257, "published": true}], "snippet_links": [{"key": "the-research-program", "type": "clause", "offset": [0, 20]}, {"key": "on-the-effective-date", "type": "clause", "offset": [36, 57]}, {"key": "years-thereafter", "type": "clause", "offset": [86, 102]}, {"key": "the-parties", "type": "clause", "offset": [176, 187]}, {"key": "mutual-written-agreement", "type": "clause", "offset": [203, 227]}], "hash": "7e88a30422bf54af33c96c1bf44e1d1c", "id": 4}, {"size": 5, "snippet": "The term of the Research Program (the \u201cResearch Term\u201d) shall commence on the Effective Date and end on the earlier of (a) completion of the activities set forth in the Research Plan and (b) the fifth (5th) anniversary of the Effective Date. The Research Term may be extended by the Parties\u2019 mutual written agreement.", "samples": [{"hash": "lrZhi7cgdiF", "uri": "/contracts/lrZhi7cgdiF#research-term", "label": "License and Collaboration Agreement (Pandion Therapeutics Holdco LLC)", "score": 31.5297737122, "published": true}, {"hash": "eLlmZ11xzcT", "uri": "/contracts/eLlmZ11xzcT#research-term", "label": "License and Collaboration Agreement (Pandion Therapeutics Holdco LLC)", "score": 31.4832305908, "published": true}, {"hash": "69PwJy5Yuvi", "uri": "/contracts/69PwJy5Yuvi#research-term", "label": "License and Collaboration Agreement (Pandion Therapeutics Holdco LLC)", "score": 31.3874053955, "published": true}], "snippet_links": [{"key": "term-of-the-research-program", "type": "clause", "offset": [4, 32]}, {"key": "on-the-effective-date", "type": "clause", "offset": [70, 91]}, {"key": "completion-of-the-activities", "type": "clause", "offset": [122, 150]}, {"key": "research-plan", "type": "definition", "offset": [168, 181]}, {"key": "by-the-parties", "type": "clause", "offset": [275, 289]}, {"key": "mutual-written-agreement", "type": "clause", "offset": [291, 315]}], "hash": "2da0246e9624e7f5ee6ef66e738cfbad", "id": 5}, {"size": 5, "snippet": "The Research Collaboration shall commence on the Effective Date and continue for a period of forty-eight (48) months (the initial \u201cResearch Term\u201d). The Parties may agree to extend the Research Term by extending the Initial Research Funding Period as explained in further detail in Section 9.2.2 below.", "samples": [{"hash": "cNKwOWCz74F", "uri": "/contracts/cNKwOWCz74F#research-term", "label": "Research Collaboration and License Agreement (Vitae Pharmaceuticals, Inc)", "score": 25.7227916718, "published": true}, {"hash": "eCIOWK5GFkW", "uri": "/contracts/eCIOWK5GFkW#research-term", "label": "Research Collaboration and License Agreement (Vitae Pharmaceuticals, Inc)", "score": 25.6926765442, "published": true}, {"hash": "hWicZoQNPs", "uri": "/contracts/hWicZoQNPs#research-term", "label": "Research Collaboration and License Agreement (Vitae Pharmaceuticals, Inc)", "score": 25.6570835114, "published": true}], "snippet_links": [{"key": "the-research-collaboration", "type": "clause", "offset": [0, 26]}, {"key": "on-the-effective-date", "type": "clause", "offset": [42, 63]}, {"key": "period-of", "type": "clause", "offset": [83, 92]}, {"key": "the-parties", "type": "clause", "offset": [148, 159]}, {"key": "to-extend", "type": "clause", "offset": [170, 179]}, {"key": "funding-period", "type": "definition", "offset": [232, 246]}, {"key": "further-detail", "type": "clause", "offset": [263, 277]}, {"key": "section-922", "type": "clause", "offset": [281, 294]}], "hash": "68e101338fc703b14d0c243d519c52c4", "id": 6}, {"size": 4, "snippet": "The Research Term commences as of the Effective Date and, unless the Agreement is earlier terminated under Article 9, or the Research Program is earlier terminated under Section 14.1, shall continue until either (a) Genentech notifies ACI of termination of the Research Term at any time following the [*****] of the Effective Date or (b) ACI notifies Genentech of termination of the Research Term at any time following the earlier of (i) the date on which the first Therapeutic Product is administered to the first human subject in a Phase I Clinical Trial, or (ii) [*****] years after the Effective Date. After [*****] months following the end of the Research Term, the JRC is no longer required to meet.", "samples": [{"hash": "84KgHjqRqR6", "uri": "/contracts/84KgHjqRqR6#research-term", "label": "Research Collaboration and License Agreement (AC Immune SA)", "score": 27.6995201111, "published": true}, {"hash": "jP428uhHxV5", "uri": "/contracts/jP428uhHxV5#research-term", "label": "Research Collaboration and License Agreement (AC Immune SA)", "score": 27.4120464325, "published": true}, {"hash": "btHBgzctqz2", "uri": "/contracts/btHBgzctqz2#research-term", "label": "Research Collaboration and License Agreement (AC Immune SA)", "score": 26.8945922852, "published": true}], "snippet_links": [{"key": "as-of-the-effective-date", "type": "clause", "offset": [28, 52]}, {"key": "the-agreement", "type": "clause", "offset": [65, 78]}, {"key": "article-9", "type": "definition", "offset": [107, 116]}, {"key": "the-research-program", "type": "clause", "offset": [121, 141]}, {"key": "section-141", "type": "clause", "offset": [170, 182]}, {"key": "termination-of-the", "type": "clause", "offset": [242, 260]}, {"key": "at-any-time", "type": "clause", "offset": [275, 286]}, {"key": "following-the", "type": "definition", "offset": [287, 300]}, {"key": "therapeutic-product", "type": "definition", "offset": [466, 485]}, {"key": "human-subject", "type": "definition", "offset": [515, 528]}, {"key": "phase-i-clinical-trial", "type": "clause", "offset": [534, 556]}, {"key": "after-the-effective-date", "type": "clause", "offset": [580, 604]}, {"key": "the-jrc", "type": "clause", "offset": [667, 674]}], "hash": "7ec7f343125f99cdde123b1c7d5020da", "id": 7}, {"size": 4, "snippet": "The initial Research Term may be extended [***] if both Parties agree in writing, at least [***] days prior to the expiry of the then-current Research Term, to extend the Research Term, such agreement to include a revised Research Plan to cover the additional work, the number of FTEs to be provided by each Party for such work and a budget for the additional work.", "samples": [{"hash": "1mqWkV876Xe", "uri": "/contracts/1mqWkV876Xe#research-term", "label": "License Agreement (Indivior PLC)", "score": 32.388092041, "published": true}, {"hash": "d4wj7lDwfls", "uri": "/contracts/d4wj7lDwfls#research-term", "label": "License Agreement (Indivior PLC)", "score": 32.1854896545, "published": true}, {"hash": "3h9UZnRUFDy", "uri": "/contracts/3h9UZnRUFDy#research-term", "label": "License Agreement (Addex Therapeutics Ltd.)", "score": 30.9575634003, "published": true}], "snippet_links": [{"key": "initial-research-term", "type": "definition", "offset": [4, 25]}, {"key": "both-parties-agree", "type": "clause", "offset": [51, 69]}, {"key": "in-writing", "type": "clause", "offset": [70, 80]}, {"key": "prior-to-the", "type": "clause", "offset": [102, 114]}, {"key": "expiry-of", "type": "clause", "offset": [115, 124]}, {"key": "to-extend", "type": "clause", "offset": [157, 166]}, {"key": "the-research", "type": "clause", "offset": [167, 179]}, {"key": "agreement-to", "type": "clause", "offset": [191, 203]}, {"key": "research-plan", "type": "definition", "offset": [222, 235]}, {"key": "additional-work", "type": "definition", "offset": [249, 264]}, {"key": "number-of", "type": "definition", "offset": [270, 279]}, {"key": "by-each-party", "type": "clause", "offset": [300, 313]}, {"key": "work-and", "type": "clause", "offset": [323, 331]}], "hash": "0ba829b3ad113e5be88ee37a0bf8a242", "id": 8}, {"size": 4, "snippet": "Legacy shall notify Primary immediately upon (i) Legacy\u2019s receipt of any notice or correspondence from Ag Partner regarding the extension, expiration, or termination of the Research Term and (ii) any expiration or termination of the Research Term, respectively, including in such notice (a) a copy of any such notice or correspondence and (b) the date of termination or expiration of the Research Term, respectively.", "samples": [{"hash": "gr57UV7Sj4Q", "uri": "/contracts/gr57UV7Sj4Q#research-term", "label": "Separation and Distribution Agreement (Viamet Pharmaceuticals Holdings LLC)", "score": 27.2669410706, "published": true}, {"hash": "1yGsEtBtepA", "uri": "/contracts/1yGsEtBtepA#research-term", "label": "License Agreement (Viamet Pharmaceuticals Holdings LLC)", "score": 27.2669410706, "published": true}, {"hash": "gYHHccDHl2X", "uri": "/contracts/gYHHccDHl2X#research-term", "label": "License Agreement (Viamet Pharmaceuticals Holdings LLC)", "score": 27.1875419617, "published": true}], "snippet_links": [{"key": "immediately-upon", "type": "clause", "offset": [28, 44]}, {"key": "receipt-of", "type": "clause", "offset": [58, 68]}, {"key": "any-notice", "type": "definition", "offset": [69, 79]}, {"key": "termination-of-the", "type": "clause", "offset": [154, 172]}, {"key": "expiration-or-termination", "type": "clause", "offset": [200, 225]}, {"key": "a-copy-of", "type": "clause", "offset": [291, 300]}, {"key": "expiration-of-the-research-term", "type": "clause", "offset": [370, 401]}], "hash": "fa2fbd5e0aa7e6c938521f68ee2285bf", "id": 9}, {"size": 4, "snippet": "The term of the Research Program (the \"Research Term\") shall begin on the Effective Date and shall continue until *** (the \"Initial Term\"), subject to extension as described below. At Wyeth's option (exercisable by providing written notice to Trubion no later than *** prior to the end of the Initial Term of the Research Program or any extension year thereof), the Research Term may be extended for up to *** additional *** periods and, thereafter, shall be renewable annually only upon mutual written agreement of the Parties.", "samples": [{"hash": "hlHc2DPcEBf", "uri": "/contracts/hlHc2DPcEBf#research-term", "label": "Collaboration and License Agreement (Trubion Pharmaceuticals, Inc)", "score": 18.0, "published": true}, {"hash": "hPIwhY9xfY4", "uri": "/contracts/hPIwhY9xfY4#research-term", "label": "Collaboration and License Agreement (Trubion Pharmaceuticals, Inc)", "score": 18.0, "published": true}, {"hash": "3HXHs8WznLr", "uri": "/contracts/3HXHs8WznLr#research-term", "label": "Collaboration and License Agreement (Trubion Pharmaceuticals, Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "term-of-the-research-program", "type": "clause", "offset": [4, 32]}, {"key": "shall-begin", "type": "definition", "offset": [55, 66]}, {"key": "on-the-effective-date", "type": "clause", "offset": [67, 88]}, {"key": "initial-term", "type": "clause", "offset": [124, 136]}, {"key": "subject-to", "type": "clause", "offset": [140, 150]}, {"key": "notice-to", "type": "definition", "offset": [233, 242]}, {"key": "prior-to-the", "type": "clause", "offset": [269, 281]}, {"key": "extension-year", "type": "definition", "offset": [337, 351]}, {"key": "agreement-of-the-parties", "type": "clause", "offset": [503, 527]}], "hash": "6fdb4966df18702d7772e5c30d0794e9", "id": 10}], "next_curs": "ClYSUGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjILEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhZyZXNlYXJjaC10ZXJtIzAwMDAwMDBhDKIBAmVuGAAgAA==", "clause": {"size": 322, "parents": [["research-program", "Research Program"], ["research", "Research"], ["definitions", "Definitions"], ["research-collaboration", "Research Collaboration"], ["collaboration", "Collaboration"]], "title": "Research Term", "children": [["research-term", "Research Term"], ["extension-of-research-term", "Extension of Research Term"], ["extension-of-the-research-program", "Extension of the Research Program"], ["term-of-the-research-program", "Term of the Research Program"], ["effect-of-termination", "EFFECT OF TERMINATION"]], "id": "research-term", "related": [["research-program", "Research Program", "Research Program"], ["research-collaboration", "Research Collaboration", "Research Collaboration"], ["development-period", "Development Period", "Development Period"], ["research-plan", "Research Plan", "Research Plan"], ["development-program", "Development Program", "Development Program"]], "related_snippets": [], "updated": "2026-02-07T04:24:37+00:00", "also_ask": ["What are the essential elements that must be included in a 'Research Term' clause to protect both parties?", "How can the duration and scope of the research term be strategically negotiated to align with business objectives?", "What are the most common risks or ambiguities in 'Research Term' clauses that could lead to disputes?", "How do courts typically interpret and enforce 'Research Term' provisions in similar agreements?", "How does the 'Research Term' clause compare to industry standards or similar clauses in competitor contracts?"], "drafting_tip": "Define the research term's start and end dates to avoid ambiguity; specify extension conditions to ensure enforceability; clarify triggers for early termination to prevent disputes.", "explanation": "A Research Term clause defines the specific duration during which research activities under an agreement are to be conducted. It typically outlines the start and end dates for the research period and may include provisions for extending or shortening the term under certain conditions, such as mutual agreement or achievement of milestones. This clause ensures that both parties have a clear understanding of the timeframe for their obligations, helping to manage expectations and avoid disputes over the timing of deliverables or project completion."}, "json": true, "cursor": ""}}